You are here
Eliquis (Apixaban) is an oral antiplatelet belonging to class of direct factor Xa inhibitors. It is manufactured by Bristol-Myers Squibb and Pfizer under the trade name Eliquis. It acts by inhibiting Factor Xa, which is a key blood clotting protein that decreases level of a thrombin, thus Eliquis indirectly decreases clot formation. Eliquis was approved by FDA on December 28, 2012, for the prevention of stroke in people with atrial fibrillation.
Eliquis is used for
- Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation
- Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery
- Treatment of Deep Vein Thrombosis
- Treatment of Pulmonary Embolism
- Reduction in the Risk of Recurrence of DVT and PE
In June 2014, patient started on Eliquis died of gastrointestinal bleeding as a complication within two months. It was observed Eliquis can increase the risk of uncontrollable bleeding, and is more prone when taken at the same time with Aspirin and non-steroidal anti-inflammatory drugs (NSAIDs).
Serious Alleged Injuries may include:
- Gastrointestinal (GI) bleeding
- Rectal bleeding
- Kidney bleeding
- Cerebral hemorrhage
- Hypovolemic shock
The first lawsuit against Eliquis was filed in July 2015. The manufacturers claim that the Eliquis is superior in safety and effectiveness as compared to Warfarin but there is lack of clear evidence in its support. Eliquis does not have an antidote to stop the bleeding complications.
Evidence to be looked for in potential cases
- 1. Usage of Eliquis
- 2. Duration of Eliquis usage
- 3. Indication for Eliquis usage
- 4. Complications and treatment after Eliquis usage
Medical Record Review and claim validation of Eliquis case should take approximately 3 hours in most instances; however, this approximation may vary in cases based on the volume of records.